Nature cancerImmunoconjugatesAnimalsHumansMiceCell Line
TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancers.
Jiaxin Ge, Joshua Urban, Sarah R DiNapoli, Bum Seok Lee, Taha Ahmedna, Tushar D Nichakawade, Brian J Mog, Steve Lu, Xuyang Li, Nikita Marcou, Stephanie Glavaris, Jacqueline Douglass, Jin Liu, Maximilian F Konig, Evangeline Watson
Published: 202510.1038/s43018-025-01069-z
Abstract
Antibody-drug conjugates (ADCs) have been remarkably successful in treating solid and hematological malignancies. Generation of ADCs for T cell cancers is challenging because the ADCs must selectively target cancerous T cells while sparing some norma…
Preview only. Read the full abstract at the source